TB-500 side effects and what the literature reports
A plain-English summary of the safety record for thymosin beta-4 — what the trials show, what is missing, and where the cautions matter most.
TL;DR
- TB-500's published safety data comes mostly from animal studies and small early-phase human trials of recombinant thymosin beta-4 in cardiac, eye, and skin conditions.
- Reported side effects in those studies were mild — headache, fatigue, occasional injection-site reactions — with no major signals at the doses studied.
- The biggest honest cautions are angiogenesis-related: anyone with active or recent cancer should avoid TB-500 unless a specialist explicitly weighs the risk.
What it is
TB-500 is a synthetic fragment based on thymosin beta-4 (TB4), a 43-amino-acid protein the body makes naturally and uses for repair, cell migration, and new blood-vessel formation. The peptide sold under the TB-500 label is widely studied as a model molecule for tissue repair. It was placed on the FDA Category 2 list in 2023. FDA removed TB-500 from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, TB-500 is not in any FDA 503A category and is not on the 503A bulks list. As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
How it works
Picture TB4 as a traffic cop at the site of an injury. It recruits the right cells to the right place, nudges new capillaries to sprout, and helps the repair crew migrate where they are needed. That recruitment-and-vessel-growth signal is what makes TB-500 interesting for healing — and exactly what makes it require care in anyone with cancer history. The same signal that helps a torn tendon can in principle help a tumor improve its blood supply (PubMed — thymosin beta-4 safety).
Who asks about it
People come to this topic before considering TB-500 for tendon, ligament, or post-surgical recovery, after reading enthusiastic but uncritical online content, or because they have a personal or family cancer history and want a careful read.
What the research says
Published early-phase trials of recombinant thymosin beta-4 — for ischemic heart disease, dry eye, and pressure ulcers — reported a generally well-tolerated profile at studied doses, with mild headache and injection-site irritation as the most common adverse events (ClinicalTrials.gov — thymosin beta-4). Long-term human safety data is limited. Most of what circulates online about TB-500 in muscle and tendon recovery is extrapolated from animal data, not large human trials.
What to know before considering it
The angiogenesis caution is the most important one. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. Gray-market supply carries quality risks the published literature does not cover. Anyone considering TB-500 for an athletic recovery use should also be aware that thymosin beta-4 is on the WADA prohibited list — a relevant data point for anyone subject to drug testing.
The Halftime POV
TB-500 sits in the same honest bucket as BPC-157: interesting biology, real animal evidence, real human trials in narrow indications, and a thin long-term safety record outside those indications. We respect the cancer-history caveat and watch the regulatory clock.
Related reading:
- TB-500 (thymosin beta-4): what this repair peptide is
- How TB-500 promotes angiogenesis and tissue healing
- TB-500: what Category 2 status means for access
- BPC-157 and TB-500: why these two are often discussed together
FAQ
Q: What side effects has TB-500 shown in studies? A: Reported effects in published trials of thymosin beta-4 include mild headache, fatigue, and injection-site reactions. The recombinant form has been studied in early human trials for cardiac, eye, and skin conditions with no major safety signals at studied doses.
Q: Is TB-500 safe with a cancer history? A: TB-500 promotes angiogenesis (in plain English: new blood-vessel formation), which is also part of how tumors grow. Anyone with active or recent cancer should avoid TB-500 unless a specialist explicitly weighs the risk.
Q: Is TB-500 still available in 2026? A: As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
Disclaimer
As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What side effects has TB-500 shown in studies?
Reported effects in published trials of thymosin beta-4 include mild headache, fatigue, and injection-site reactions. The recombinant form has been studied in early human trials for cardiac, eye, and skin conditions with no major safety signals at studied doses.
Is TB-500 safe with a cancer history?
TB-500 promotes angiogenesis (in plain English: new blood-vessel formation), which is also part of how tumors grow. Anyone with active or recent cancer should avoid TB-500 unless a specialist explicitly weighs the risk.
Is TB-500 still available in 2026?
As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
Keep reading
Buying peptides online? There is a route with labs first and a licensed physician.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.